Breast cancer screening tool predicts patient response to immunotherapies

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

On Feb. 2, Nature Medicine published the results of a large, randomized, prospective clinical trial in the nascent and some say, fringe, field of chrono-oncology—the study of how natural biological rhythms might impact cancer outcomes.

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Clinical Trials & Tribulations

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

I performed my first colonoscopy as a board-certified gastroenterologist more than 20 years ago, at a time when the procedure was firmly established as the “gold standard” for colorectal cancer screening.

July 02, 2026

Vol.52 No.26

By Paul J. Limburg

Clinical Trials & Tribulations

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

For decades, we have faced a central challenge in colorectal cancer screening. One in three eligible Americans—over 50 million people—remain unscreened despite established methods like colonoscopy or stool-based tests existing for decades. This gap persists even though early detection saves lives, and even as colorectal cancer is now the number one cancer killer for Americans under 50.

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Breast cancer screening tool predicts patient response to immunotherapies

YOU MAY BE INTERESTED IN

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Breast cancer screening tool predicts patient response to immunotherapies

YOU MAY BE INTERESTED IN

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

Is it time to re-assess the practice and practicality of screening colonoscopy?Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

More than 50 million Americans remain unscreened for colon cancerNew guidelines offer another option

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Never miss an issue!

Login

A chronotherapy study in Nature Medicine showed dramatic results. Then it was retracted.
The phase III trial claimed a staggering boost to OS and PFS when immunochemotherapy was given before 3 p.m.

Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives

More than 50 million Americans remain unscreened for colon cancer
New guidelines offer another option